The Aravind Managed Eye Care Services (AMECS) team Retreatunderstand the eye care infrastructure, current Structuring the Activities of Managed Eye Careperformance and the unmet eye care needs inRajasthan. Based on this a roadmap for The goal of performing 500,000 surgeries annually byimplementation has been developed. the year 2015 through managed eye hospitals requires the right structure, staffing and processes. MichaelFormal Inauguration of the Priyamvada Birla Aravind Johnson, an assignee from IBM placed by Adopt-a-Eye Hospital Business, helped in refining and defining the role ofKolkata, May 1, 2007 this new structure named as “Aravind Managed Eye Care Services”. Its broad roles are building partnerPriyamvada Birla Aravind Eye Hospital, Kolkata relationships, establishing hospitals and running themoved into its new five storied facility and was hospitals with a seamless interface to the Aravind Eyeinaugurated by Shri Somnath Chatterjee, Honorable Care System and create synergy. Narotam SekhsariaSpeaker, Lok Sabha. The new facility is equipped Foundation has given a generous grant to build theand staffed to be a tertiary level hospital and offers capacity of AMECS to reach its goal.all advanced sub-specialty eye care. To take this forward and work out short-term goalsInauguration of Sudarshan Netralaya and strategies, a retreat was organised in LAICO onAmreli, July 20, 2007 March 21- 22, 2008. The retreat included reflection and learning from the experience of establishingThe third Managed Eye Hospital “Sudarshan three managed eye hospitals resulting in theNetralaya” in association with Nagardas Dhanji documentation of various process involved. TheShanghvi Trust at Amreli, Gujarat was inaugurated retreat in addition to the AMECS team included theby Swami Shri Sachithanandji. This 30 bed eye Senior Leadership Team of Aravind, senior doctors,hospital meets the secondary eye care needs of and administrators of the three managed eyeAmreli and the neighbouring districts. hospitals and a team of project students from University of Michigan. AMECS: PERFORMANCE: APRIL 2007 - MARCH 2008 Hospital OUTPATIENTS Hospital SURGERIES Total Eye camps Total Eye camps 4,974 13,113 M P Birla Eye Hospital, Kolkata,West Bengal 45,810 26,964 72,774 1,365 8,139 2,521 41,621 109,993 2,097 1,156 15,634 IGEHR, Amethi, Uttar Pradesh 68,372 13,923 38,565 5,348 Sudarshan Nethralaya, Amreli, Gujarat 24,642 Total 138,824 82,508 221,332 8,436 14,643 23,07950
ARAVIND EYE BANKS 2007-2008 E ye banks located at Aravind Eye Hospitals at TRAININGS OFFERED Madurai, Tirunelveli, Coimbatore and Puducherry provide corneas and other eye 1. Physician Training was offered for four doctors tissue for sight-restoring transplant surgery. from Eye donation centres of Rotary club ofThe eye banks are also involved in various training Devakottai, Rotary club of Ottanchatram andand awareness creating activities. In the last year, Lions club of Velankannithey took new initiatives to improve collection ofeye balls. Various awareness programmes were 2. Eye Bank Technician Training was given to aarranged in colleges, self-help groups, Lions Clubs, technician from the Institute of Medical SciencesRotary Clubs and in several non-profit organisations. and Sum Hospital, Bhubaneshwar.Each year the Eye donation fortnight is observed Aravind Eyes Used for Cornealfervently in all Aravind Eye Banks. Joining hands Eye Banks Received Transplantationwith several community organisations andcompassionate corporations, several awareness Madurai 1,803 530programmes such as public rallies, interactive Tirunelveli 58 77sessions through the radio and television are held. Coimbatore 857 308 PuducherryAwareness Rally on eye donation at Aravind- Madurai Total 184 106 2,902 1,021 Evaluation process 51
52
DR. G. VENKATASWAMY EYE RESEARCH INSTITUTEARAVIND MEDICAL RESEARCH FOUNDATION 2007-2008F rom the initial days of performing large and paediatric ophthalmology, as well as its rapid scale operational studies on barriers of strides in the field of tele-ophthalmology with service delivery, research at Aravind has remote consultations and teleconferencing betweengrown to encompass all areas of research in hospitals, Aravind is poised as never before to takeophthalmology - basic, clinical, operations research on new challenges in research.including community outreach and, with theestablishment of Aurolab, product development. To ON GOING PROJECTSintegrate all these, the Dr. G. Venkataswamy EyeResearch Institute was formed to be the nodal body. BASIC RESEARCHNow with the establishment of Centres of Excellence The major ongoing basic research studies are:within Aravind’s speciality clinics, alongside itscontinued emphasis on academic rigor and its recent - Identification of candidate genes and screeningthrust on developing comprehensive service delivery for polymorphisms of genes associated with Typemodels in areas like diabetic retinopathy, glaucoma 2 diabetic retinopathy - Understanding the molecular genetics of inherited congenital cataractProf. Muthukkaruppan with Junior Scientist Ms. GowriPriya and JuniorResearch Fellow Ms. Murugeswari 53
- Congenital rubella syndrome – an eye hospital - Correlation of Macular and RNFL thickness on based investigation OCT in Primary Open Angle Glaucoma- Genetic and functional dissection of FOXL2 gene - Patient-reported barriers to glaucoma medication involved in the pathogenesis of blepharophimosis access, use, and adherence in Southern India syndrome (BPES) - Plasma Biomarkers in Primary Open Angle- Studies on the proangiogenic and vascular growth Glaucoma - A Pilot Study and Analysis factors in relation to the pathogenesis of Eales’ - Thinner Corneas correlate with severity of disease and diabetic retinopathy glaucomatous optic nerve damage in Glaucoma- Identification, characterisation and quantification - IOP Elevation following Intravitreal Triamcinolone of human buccal epithelial stem cells for corneal - Efficacy of Intravitreal Bevazizumab in surface reconstruction Management of Neovascular Glaucoma- Will cytoskeletal drugs prevent Posterior - Rubeosis Iris- Pre-injection phase and regression Capsular Opacification (PCO)? of the new vessels 2 weeks after intravitreal- The isolated human limbal basal cells with high Bevazizumab levels of p63 expression and large N/C ratio - Efficacy of topical Dorzolamide as compared to possess slow – cycling property Brimonidine in prevention of Post operative IOP- Pathogenic mechanism of uveitis associated with spike following Trabeculectomy combined with Leptospiral infection phacoemulsification and Foldable IOL Implantation.- Molecular genetic analysis of Corneal Endothelial - Relationship of Intraocular Pressure to Postural Dystrophies Change in Southern Indian Patients with and- Proteomic study of the tears of patients with without Glaucoma fungal keratitis - Factors Associated with Patients’ Adherence with- Ocular infection and multiplex PCR Anti-glaucoma Therapy in South India- A genetic component to the INDEYE study of - Awareness of glaucoma in an urban and rural cataract and age-related macular degeneration in population in Puducherry, South India. India - Safety and efficacy of manual small incision- Corneal Surface reconstruction using cultured cataract surgery for phacolytic glaucoma Human Limbal Epithelial Cells - Self-Reported Barriers and Strategies to Better- Identification of genetic defects occurring in Follow-up among Glaucoma Patients in South India Indian Oculocutaneous (OCA) and Ocular - Consensual Ophthalmotonic Reaction (COR) Albinism (OA) families following Trabeculectomy / PhacotrabeculectomyCLINICAL RESEARCH - Macular thickness variability in primary openThe major clinical research studies underway are: angle glaucoma patients using optical coherence tomography- The Madurai Study of Low Vision Children in - Comparative study of the success rate of laser Blind Schools DCR with or without use of Aluminum foil coated- Posurdex–Intermediate and Posterior Uveitis Study protectors for middle turbinate- HLA-DR determination of Vogt-Koyanagi-Harada - Dacryocystorhinostomy: A comparison of syndrome and Sympathetic Ophthalmia in South external versus transcanalicular endolaser DCR Indian patients - National Retinoblastoma Registry- A Double –masked, Placebo-controlled, - How valid (sensitive and specific) is teacher’s multicentric, parallel group, dose ranging study to screening for refractive errors as compared to that assess the efficacy and safety of LX211 as done by trained refractionists? therapy in subjects with non-infectious - Screening for 1000 children in Blind schools intermediate, anterior and intermediate, posterior (One year Project) or pan-uveitis - Optic atrophy in children in South India- To compare the long term effects of Timolol 0.5% - Clinical profile with Ocular and Oculocutaneous and Latanoprost on central Corneal Thickness Albinism at a tertiary care centre54
- Role of patient counselling on visual experiences MS. J. KANAGAVALLI, November 2007 - Studies on in patient’s undergone phacoemulsification under Myocilin (TIGR/MYOC) gene mutations and topical anaesthesia. Myocilin protein in Indian patients with Primary Open Angle Glaucoma.- Evaluation of a capsule cleaning device on lens epithelial cells in rabbits MS. ARPITHA, February 2008 - Identification, Characterisation, Enrichment and invitro- Comparative study of surgical and visual outcome maintenance of Human Corneal Epithelial Stem in coaxial phacoemulsification, bimanual phaco Cells”. emulsification and Microincision coaxial phaco emulsification using alcon infiniti (Ozil) vision Overseas Associateship Award system DR. P. SUNDARESAN, Senior Scientist was selected by- An evaluation of the safety and efficacy of Ministry of Science and Technology, Department of moxifloxacin AF ophthalmic solution 0.5% for Biotechnology, Government of India for the the treatment of bacterial conjunctivitis in India Overseas Associateship award. He went to Molecular Ophthalmic Research Laboratory, University of- A study to evaluate the clinical and microbial Iowa, Iowa city, Iowa, USA for three months (April efficacy of 0.6% ISV 403 compared to to June 2007) and worked with Dr. Edwin Stone on VIGAMOX in the treatment of bacterial Molecular genetics on Leber Congenital Amaurosis. conjunctivitis He visited several institutes, attended ARVO 2007 meeting and met several eminent senior researchers- Steroids for Corneal Ulcers Trial (SCUT) and ophthalmologists.- Mycotic Ulcer Treatment Trial (MUTT) A RARE HONOURAurolab Clinical Trials Dr. G. Venkataswamy Eye Research Institute is- Posterior Capsular Opacification after privileged to have Dr. A.P.J. Abdul Kalam, Professor implantation of Square edge PMMA, round edge of Technology & Technical Education, Anna PMMA and Acrysof intraocular lenses: A University, Chennai, formerly the Honorable Prospective, Randomised Comparative Trial President of India as the Visiting Professor from July 30, 2007.- Clinical evaluation of Hydrophobic Foldable IOLs Prof. Astrid Fletcher with Prof. Muthukkaruppan, Dr. P. Namperumalsamy, Dr. R. D. Ravindran and- Safety and Effectiveness of Yellow Intraocular Dr. Sundaresan for the INDEYE collaborative project Lenses between AMRF and London School of Hygiene and Tropical Medicine.- Comparative study of indigenous Green Laser with already available Green Laser- Evaluation of Auro-tube in Conjunctivodacryocystorhinostomy (CDCR)- Effect of Square Edge PMMA IOL in Preventing Lens Epithelial Cell Migration in Paediatric Cataract Surgery: A Randomised Controlled Trial- Randomised controlled trial of Aurolas 532-I-1 with already available green laser in Proliferative Diabetic RetinopathyPH.D AWARDEDMR. G. NEETHIRAJAN, April 2007 - Molecular Analysisof PAX6 gene in Indian aniridic patients.MS. GOWRIPRIYA CHIDAMBARANATHAN, August 2007 –Aetiology and Pathogenic Mechanism of Uveitisassociated with Leptospirosis. 55
56
AUROLAB 2007-2008R EACHING OUT WITH RENEWED Aurolab has commenced operations in the new COMMITMENT facility and each division is expanding its capacity and upgrading its technology to take advantage of In the financial year 2007-2008, Aurolab the available space. Various audits have beenrenewed its commitment to aiding the elimination of conducted and completed successfully. All divisionsneedless blindness, with the opening of an elegant of Aurolab are gearing up to meet the growingnew state-of-the-art manufacturing facility. On expectations of the organisation. Each division isSeptember 30, 2007 Dr. Allen Foster, President, working on developing new high quality productsChristian Blind Mission inaugurated the building that will be made available at affordable prices.during a special ceremony attended by hundreds of Aurolab’s Hydrophobic Acrylic Lens, Aurovue, hasAurolab partners and well-wishers from across the been well-received in the market, and Aurolab nowcountry and around the world. The new facility is looks to build on this position of strength and addlocated in a sprawling campus amidst the lush more value to the product. Its suture needle divisiongrounds of Aurofarm that sets the atmosphere for is in the process of upgrading its technology todedicated work, while the beautiful design of the manufacture absorbable sutures, while thebuilding inspires employees to do even better what Pharmaceutical division has launched its SodiumAurolab has been doing for the past sixteen years.Dr. Allen Foster unveiling the inaugural plaque at the inaugural ceremony of Aurolab’s new facility 57
hyaluronate, “Aurogel” to enable better control and FACTS ON THE NEW FACILITYsafety during Phacoemulsification surgeries.Aurolab’s instruments division has improved the Since 1996 Aurolab was functioning in LAICOquality of the bipolar cautery significantly and is Building. Aurolab felt the need for more space forcurrently working on new products like Monopolar growth and expansion. Recognising this, thecoagulator, Digital vision testing etc., and its blades foundation stone for the new facility was laid by ourdivision has been improving manufacturing process founder Chairman Dr.G.Venkataswamy onto deliver consistent high quality results. August 21, 2005.INAUGURATION OF AUROLAB'S NEW The factory is built up with 110,000 sq.ft. operatingFACILITY area including the 20000 sq.ft of clean-rooms. The new facility is constructed as per the internationalAurolab’s new facility was inaugurated at regulations like Schedule M, USFDA and UK MHRA.Veerapanchan, in the beautiful Aurofarm complex,by Dr. Allen Foster, President, Christian Blind The manufacturing area is divided as Classified areaMission, on September 30, 2007. and Unclassified area. All critical operations like filling, packing etc are to be carried out in theFelicitations were offered by David Green, classified area. Classified areas are featured with PUConsultant, US; Suzanne S. Gilbert, Director, Centre painted walls, self leveling epoxy floors, jointlessfor Innovation in Eye Care, Seva Foundation; Aluminium false ceiling, metal doors, interlocks,Dr. R. Pararajasegaram, Consultant, World Health AHUs, coved corners, GMP drains etc.Organisation, Geneva; Karumuttu T. Kannan,Managing Director, Thiagarajar Mills, Madurai and The facility includes dedicated state-of-the-artMr. S. Rethinavelu, President, Tamil Nadu Chamber microbiology lab, Water purification system, Wetof Commerce and Industry. Lab, Instrument lab, Utility block etc. It is well equipped to handle all microbial tests and shelf lifePraising the efforts of the founder, they said at a time studies. A comprehensive water purification systemwhen everyone exercised more caution than consisting Reverse Osmosis, Electro Deionizationoptimism while considering introduction of and Ultra filtration has been installed to generate andintraocular lens (IOL) in developing countries, it was distribute the pharmaceutical grade waters.Dr. Venkataswamy’s proactive approach whichfacilitated introduction of IOL in the country. As the manufacturing arm of the Aravind Eye CareCommending the services rendered to society by System, Aurolab’s unique contribution to eye careAECS they mentioned that Aravind had played a service delivery in the developing world ismajor role in etching the name of the city in the tremendous and it is now better poised than ever toworld map. serve a growing number of people in need.Aurolab staff quarters by the picturesque quarry lake. The manufacturing facility is seen at a distance on the far right58
AUROLAB STAFF QUARTERS the doctor by providing excellent space in the anterior chamber and protects the cornealFollowing the production operations in the new endothelium cells during phacoemulsification.facility, the aurolab production staff moved to their Unlike other such products available in the marketown quarters on February 24, 2008. Situated in the today, this product does not require refrigeration.Aurofarm, just as the manufacturing facility, thequarters are spacious with a beautiful quarry lake PRODUCTS TO BE LAUNCHEDand garden all around. ASPHERIC IOL: In this type of lens either one orNEW PRODUCTS both surfaces will be aspherical, conic or modified conic in shape. This lens will help improve theRetieye, August 2007 quality of vision for patients with pupil size greater than 3.0 mm.Retieye is an eye ball model designed forophthalmologists to practice indirect ophthalmo- ABSORBABLE SUTURES: Aurolab plans to supplyscopy and photocoagulation. This eye ball model PGA, a braided synthetic absorbable multifilamentwith replaceable retinal films quickens the learning made of polyglycolic acid and coated withcurve for the practitioner. Designed and developed polycaprolactone and calcium stearates, whichwith valuable guidance from Aravind Retina render the thread extremely smooth, soft and knotspecialists, the product has found good acceptance safe. Aurolab will supply these sutures in variouswith the retinal fraternity in India and abroad. sizes to be used for different surgeries.Aurogel, April 2008 FRONTALIS SUSPENSION SET: This is used for frontalis suspension in patients with significantAurolab’s Pharmaceutical division launched its ptosis and poor levator function. Since the product isSodium Hyaluronate “ Aurogel”. This product aids very expensive in the market, Aurolab plans to produce this to make it affordable to all. OCUBLUE PLUS: This dye has the optimum qualities of superior staining ILM at lower concentrations as compared to the more expensive and toxic alternatives like ICG. Aurolab plans to produce this dye which makes the delicate manoeuvre of ILM peeling much safer and efficient, with superior functional outcomes for patients. 59
MAJOR OPTHALMOLOGY CONFERENCES OTHER NEWS AND EVENTSAND TRADE FAIRS Aurolab gets CE Mark for more products likeAurolab actively participated in trade exhibitions at Polyester, Polypropylene Sutures and CTR CE, anthe following conferences to promote Aurolab abbreviation of Conformité Européenne, is aproducts. The participation on various occasions mandatory European marking for certain productprovided Aurolab members an opportunity to meet groups to indicate conformity with the essentialthe customers and reinforce, update on the products. health and safety requirements set out in EuropeanApart from national ophthalmic meets and forums, Directives.Aurolab participated in the following internationalmeets in 2007-08. Aurolab is the first Indian Ophthalmic products manufacturer to get CE mark for intraocular lenses in- Middle East African Council of Ophthalmology as early as 1999. Apart from the major products from (MEACO) Conference at Dubai, March 29 - IOL, Sutures and Pharma that are already CE certified, April 1 a list of new and important products have also been added recently. Aurolab’s Auroring - Modified Capsular- XXV Congress Of European Society for Cataract Tension Rings, Aurobond - Polyester Suture Needles, and Refractive Surgeons at Stockholm, Sweden, Aurolene - Polypropylene Suture needles and Capsular September 8-12, 2007 Tension Segment have been approved for CE mark. A few models of hydrophilic foldable lenses have also- Medical Technology Exposition (MEDTEC) at been CE marked. Galway, Ireland, September 19-20 TRAINING ON FAILURE MODE AND EFFECT- 111th Annual Meeting of the American Academy ANALYSIS (FMEA) of Ophthalmology at New Orleans, Louisiana, November 10-13, 2007 Aurolab conducted FMEA Training Program on July 15, 2007. All QA Managers, ProductMEDICA TRADE FAIR Development Engineers and other relevant staff whoDusseldorf, Germany, November 15-17, 2007 are responsible to process and design developments participated in this training program. It was a veryThis is the hub of medical trade and the visit to this useful training program to implement riskfair helped Aurolab to identify potential customers management process in line with standardand suppliers all over the world and certainly it requirements. Mr. Sasikumar from Fouryes TQMwould increase their exposure towards EU nations. Consultants gave training about FMEA. It is a Chennai based company and has given training toAUDITS about 500 companies in all over India.When Aurolab shifted its operations to the new AUROLAB DAY CELEBRATIONSmanufacturing premises at Veerapanchan andcommenced production, the new facility audits were For the first time, on their own, Aurolab celebratedconducted by certification bodies. The CE its anniversary on January 23, 2008. All cadre ofcertification audit was conducted on February 04-05, Aurolab’s participated enthusiastically. Mr. Vishnu2008 by TUV Rheinland, Germany. Since intraocular Prasad, Manager- International Marketing welcomedlens has been notified as drugs in India recently, the the gathering. Mr. P. Balakrishnan, Managingfacility audit was conducted by Drug Control Director presented the Annul report of Aurolab. TheDepartment, Chennai on February 18, 2008. various department staff displayed the achievements and aspirations of their division in unique ways thatThe ISO certification audit was conducted by UL included skits, singing and dancing apart from slideIndia Pvt. Ltd., Bangalore. presentations. Mr. R. D. Sriram, Director – Operations spoke on the future plans of AurolabAll audits were completed successfully and the followed by address by Dr. G. Natchiar, Vice-auditors were very satisfied with the processes. The Chairman of Aravind Eye Care System.certificates with revised address and including newproducts are to be received soon.60
ACCOLADESBHEESHMA AWARD A RARE DISTINCTIONThe Bheeshma Award was conferred upon Dr. R. Ramakrishnan, CMO of Aravind-TirunelveliDr. P. Namperumalsamy for his contribution in the has been accorded a rare distinction of being invitedfield of medicine on April 25, 2007 by The Ashram by Dr. George Spaeth to be a distinguished memberschool, Chennai at their 15th Annual Day Function at of the International Fellow of Spaeth SocietyKamaraj Memorial Hall, Chennai. (IFSS). Dr. Ramakrishnan has been trained by Dr George L Spaeth at Wills Eye Hospital in 1989.ANTÓNIO CHAMPALIMAUD VISIONAWARD FOR ARAVIND EYE CARE SYSTEM FARM FEST-2008The Champalimaud Foundation presented the Aravind-Puducherry participated in the XXVIIinaugural Antonio Champalimaud Vision Award to Flower, Vegetable and Fruit show, Farm fest-2008,Aravind Eye Care System at a special ceremony held conducted by the Department of Agriculture,in Lisbon, Portugal. Dr. P. Namperumalsamy. Government of Puducherry, and won the First PrizeChairman, Aravind Eye Care System received the for the Ornamental Garden and Herbal Garden andaward. Second Prize for the Kitchen Garden.The award carries with it 1 million Euros. The HIGHEST ROTARY AWARDceremony was held in the presence of the Presidentof the Portuguese Republic, Aníbal Cavaco Silva. Rotary movement has conferred its prestigious “ForThe award ceremony featured speeches from Leonor the Sake of Honor Award” to Dr. M. Srinivasan,Beleza, President of the Champalimaud Foundation, Chief of Cornea clinic, Aravind Eye Hospital, onProfessor Alfred Sommer, President of the Jury, December 7, 2007. In a rare gesture, and inDr. P. Namperumalsamy, Chairman, Aravind Eye recognition of the eye care services being renderedCare System, and Dr. Aníbal Cavaco Silva, President by Aravind, the office bearers and members ofof the Portuguese Republic. Rotary club of Madurai West came to Aravind to confer the award on Dr. M. Srinivasan. Mr. Rajadurai, Governor, Rotary International District-3000, conferred the award.Dr. P. Namperumalsamy receiving the Antonio Dr. M. Srinivasan receives the‘ For the Sake of Honour’Champalimaud Vision Award in Lisbon, Portugal Award from the Rotary Movement 61
‘ADMINISTRATOR OF THE YEAR’ AWARDMr. RD. Thulasiraj, Executive Director, LAICO hasbeen chosen as the ‘Administrator of the Year’.The awards were introduced last year by GEHealthcare in association with Info India to honourindividuals and institutions for their outstandingcontribution to healthcare. Mr. Sanil Joseph, Faculty,LAICO received the award on behalf ofMr. R.D. Thulasiraj.YOUNG INVESTIGATOR AWARD – ASIA – Dr. Shivayogi Kusagur receiving the Best Poster Award inARVO lacrimal categoryThe Young Investigator Award in Basic Science wasgiven to Ms. Murugeswari for the best posterpresentation at the ASIA-ARVO 2007 meetingconducted at Singapore from March 2-5.BEST POSTER AWARDS Best Poster award in Lacrimal Category was won by Dr. Shivayogi Kusagur for his poster on for theAravind Oculoplasty specialists won three awards at poster on Dacryocystorhinostomy: A comparison ofthe Joint Meeting of the Oculoplastics Association of External Versus Transcanalicular endolaser.India & Asia Pacific Society of Ophthalmic Plasticand Reconstructive Surgery held at Hyderabad on Best Photograph in Imaging Photography CategoryDecember 14-16, 2007. was won by Dr. Usha Kim for the ‘Double Globe?’ - CT scan photograph. Best Poster award in orbit category was won by Dr. Maneksha Velu, for his poster on Ocular Adnexal lymphoma: A Clinic Histopathological analysis in a tertiary eye care centre. Ms. Murugeswari, received the Young Investigator Award in Basic Science for the best poster presentation at the ASIA-ARVO 2007 meeting, at Singapore from March 2-5, 2007.62
PARTNERS IN SERVICEFOR SERVICE DELIVERY, TRAINING AND FOR RESEARCHOTHER DEVELOPMENTAL ACTIVITIES - Allergan Pharmaceuticals, USA- Acumen Fund, USA - Francis I.Proctor Foundn. for Research in- Adopt-a-Business, UK- Alcon Laboratories Inc, USA Ophthalmology, UCSF, USA- Canadian International Development Agency, - Indian Council of Medical Research, India - International Centre of Eye Health, UK Canada - Indian Institute of Technology, Chennai- Carl Zeiss Meditec, Germany - London School of Hygiene & Tropical Medicine,- CBM International, Germany- Combat Blindness Foundation, USA UK- Essilor, India - Madurai Kamaraj University, India- Friends of Aravind, USA - National Eye Institute, USA- Google Foundation, USA - Royal Tropical Institute, Netherlands- Indian Institute of Management, Bangalore, India - University of Iowa, USA- Indian Space Research Organisation, India - World Health Organization, Switzerland- International Federation of Eye Banks, USA - Singapore National Eye Centre, Singapore- Indian Overseas Bank, India - Tamil Nadu Dr. M.G.R. Medical University,- International Agency for Prevention of Blindness- International Eye Foundation, USA Chennai, India- Lavelle Fund for the Blind, USA - Defence Research & Development Organisation,- Lions Clubs International Foundation, USA- ORBIS International, USA Government of India- Pegasus Institute for Excellence, India - Department of Biotechnology, Government of- Project Impact, USA- Rotary International, USA India- Right to Sight, Ireland - Department of Science & Technology,- Seva Service Society, Canada- Seva Foundation, USA Government of India- Sight Savers International, UK - University of Wisconsin, Madison- State Bank of India, Madurai - National Institute of Nutrition, Hyderabad.- Sun Foundation, Chennai- TIFAC-CORE, Department of Science & Technology, Government of India- Topcon, Japan- University of Michigan, USA- VISION 2020 – The Right to Sight, India- W2 Consulting, UK- World Diabetes Foundation, Denmark- University of California, Berkeley, Dept of Computer Science- Fred Hollows Foundation, Australia. 63
ARAVIND EYE CARE SYSTEM ARAVIND EYE HOSPITALS & POSTGRADUATE INSTITUTE OF OPHTHALMOLOGYCENTRAL OFFICE RUN BY GOVEL TRUST ARAVIND–MADURAIChairman BOARD OF TRUSTEES Chief Medical Officer / ProfessorDR. P. NAMPERUMALSAMY MS., FAMS DR. S.R. KRISHNADAS DO., DNBVice Chairman PresidentDR. G. NATCHIAR MS., DO ER. G. SRINIVASAN Administrator / ReaderDirector DR. S. ARAVIND MS., MBADR. M. SRINIVASAN MS., DO Trust SecretaryJoint Director DR. N.VENKATESH PRAJNA RETINA - VITREOUS CLINICDR. R.D. RAVINDRAN MS., DO Members Chief / ProfessorFINANCE DR. G. NALLAKRISHNAN DR. R. KIM DO., DNBDirector DR. P. NAMPERUMALSAMYG. SRINIVASAN BE., MS DR. G. NATCHIAR Professors MRS. MEENAKSHI NALLAKRISHNAN DR. P. NAMPERUMALSAMY MS., FAMSHUMAN RESOURCES MRS. LALITHA DR. DHANANJAY SHUKLA MS, FAMSDirector DR. R. KIM DR. K. NARESH BABU MSDR. G. NATCHIAR MS., DO DR. S. ARAVINDSenior Manager PRESIDENT, ROTARY CLUB, MADURAI MAIN Assistant ProfessorsPREETHI PRADHAN MSW BRANCH - (EX-OFFICIO) DR. ANAND RAJENDRAN DO., DNB., FRCS (G) DR. T.P. VIGNESH MSIT & SYSTEMS DR. UMESH CHANDRA MSDirector DR. SOMNATH MSR.D. THULASIRAJ B.SC., MBA DR. JAY KALLIATH MSSenior ManagerB.S. GANESH BABU M.COM., MS INTRAOCULAR LENS & CATARACT CLINICEDUCATIONResidency Training Chief / ReaderDR. N. VENKATESH PRAJNA DO., DNB., DR. G. HARIPRIYA ARAVIND MSFRCOPHTH.Mid Level Ophthalmic Personnel ProfessorDR. USHA KIM DNB DR. G. NATCHIAR MS., DOARAVIND COMMUNICATIONS ReadersMS. CHITRA THULASIRAJ B.SC DR. S. ARAVIND MS., MBA DR. K. ILANGO DO., DNBPURCHASES. JAYACHANDRAN MHM Assistant Professors DR. S. MAHESH KUMAR DO., DNBOUTREACH DR. KAVITA VADI MSR. MEENAKSHI SUNDARAM MHM DR. A. KOWSALYA DO., DNB DR. P.M. ARAVIND MS DR. PRASHANT RAPHAEL MS DR. MARIE FREDRICK MOUTHAPA DO, DNB DR. S. BALAMURUGAN, MS DR. S. TAMILARASI MS DR. N. VIDHYA, MS Medical Officers DR. V.P. RAVICHANDRAN DO DR. PAMONA SAMSON DO DR. RUPA DO Assistant Professor DR. H. KASTHURI BAI DO DR. P.S. VIVEK, DO64
Search
